Skin Diseases, Papulosquamous News

Skin Diseases, Papulosquamous	Welcome, Profile Billing Logout

«1 2 345 6 7 8 9 10 11 12 13...18 19 »

||||||||||  toreforant (JNJ-38518168) / J&J
Trial primary completion date:  A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis (clinicaltrials.gov) -  Dec 12, 2015
P2, N=66, Recruiting,  Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Sep 2015 --> Feb 2016

||||||||||  triamcinolone acetonide topical / Generic mfg.
Trial suspension:  DIPSO: Steroids Added to Dithranol and Narrow Band UVB(Ultraviolet B) (UVBnb) in Psoriasis (clinicaltrials.gov) -  Dec 12, 2015
P4, N=88, Suspended,  Sponsor: University of Zurich
Trial primary completion date: Sep 2015 --> Feb 2016 Recruiting --> Suspended

||||||||||  calcipotriol/betamethasone dipropionate / Generic mfg.
Trial completion:  PSTaclonex: Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris (clinicaltrials.gov) -  Dec 12, 2015
P=N/A, N=20, Completed,  Sponsor: Wake Forest University
Recruiting --> Suspended Active, not recruiting --> Completed

||||||||||  Stelara (ustekinumab) / J&J
Trial completion:  PSTELLAR: A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis (clinicaltrials.gov) -  Dec 12, 2015
P3, N=480, Completed,  Sponsor: Janssen Biotech, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed:  CRADLE: A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers (clinicaltrials.gov) -  Dec 5, 2015
P1, N=17, Active, not recruiting,  Sponsor: UCB BIOSCIENCES, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting

||||||||||  Skilarence (dimethyl fumarate) / Almirall
Trial completion, Enrollment change:  LAS41008 in Moderate to Severe Chronic Plaque Psoriasis (clinicaltrials.gov) -  Dec 4, 2015
P3, N=839, Completed,  Sponsor: Almirall, S.A.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=690 --> 839

||||||||||  Januvia (sitagliptin) / Merck (MSD)
Trial primary completion date:  Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP) (clinicaltrials.gov) -  Dec 4, 2015
P2, N=120, Recruiting,  Sponsor: University College Dublin
Active, not recruiting --> Completed | N=690 --> 839 Trial primary completion date: Feb 2016 --> Oct 2016

||||||||||  Stelara (ustekinumab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Enrollment closed, Enrollment change, HEOR:  Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation (clinicaltrials.gov) -  Dec 4, 2015
P=N/A, N=26, Active, not recruiting,  Sponsor: University Hospital Case Medical Center
Trial primary completion date: Feb 2016 --> Oct 2016 Recruiting --> Active, not recruiting | N=40 --> 26

|||||||||| Enrollment closed, Trial primary completion date: The NOR-SWITCH Study (clinicaltrials.gov) - Nov 28, 2015
P4, N=500, Active, not recruiting, Sponsor: Diakonhjemmet Hospital
Recruiting --> Active, not recruiting | N=40 --> 26 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Jul 2016

||||||||||  Enbrel (etanercept) / Pfizer, Amgen
Trial completion:  Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab (clinicaltrials.gov) -  Nov 26, 2015
P4, N=64, Completed,  Sponsor: Amgen
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Jul 2016 Active, not recruiting --> Completed

||||||||||  Xeljanz (tofacitinib) / Pfizer
Clinical:  OPAL BEYOND: Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors (clinicaltrials.gov) -  Nov 19, 2015
P3, N=390, Active, not recruiting,  Sponsor: Pfizer
Active, not recruiting --> Completed Recruiting --> Active, not recruiting

||||||||||  atorvastatin / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date:  Influence of Atorvastatin on Psoriasis Severity and Endothelial Function (clinicaltrials.gov) -  Nov 17, 2015
P3, N=0, Withdrawn,  Sponsor: shmuel fuchs
Recruiting --> Active, not recruiting N=110 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2014 --> Apr 2015

||||||||||  sonelokimab (M1095) / Avillion, MoonLake Immunotherap
Trial completion:  Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects (clinicaltrials.gov) -  Nov 11, 2015
P1, N=41, Completed,  Sponsor: Merck KGaA
N=110 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2014 --> Apr 2015 Active, not recruiting --> Completed

||||||||||  Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date, Adherence:  Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice (clinicaltrials.gov) -  Nov 9, 2015
P=N/A, N=140, Recruiting,  Sponsor: AbbVie
Active, not recruiting --> Completed Trial primary completion date: Jul 2016 --> Mar 2017

|||||||||| Trial completion, Enrollment change, Trial primary completion date: Effect of Vitamin D Supplementation on Metabolic Parameters of Patients With Psoriasis (clinicaltrials.gov) - Nov 5, 2015
P=N/A, N=39, Completed, Sponsor: Pontificia Universidad Catolica de Chile
Trial primary completion date: Jul 2016 --> Mar 2017 Recruiting --> Completed | N=60 --> 39 | Trial primary completion date: Oct 2015 --> Apr 2015

||||||||||  neihulizumab (ALTB-168) / AltruBio
Enrollment closed, Enrollment change:  A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis (clinicaltrials.gov) -  Oct 29, 2015
P2, N=20, Active, not recruiting,  Sponsor: AbGenomics B.V Taiwan Branch
Recruiting --> Completed | N=60 --> 39 | Trial primary completion date: Oct 2015 --> Apr 2015 Recruiting --> Active, not recruiting | N=15 --> 20

||||||||||  Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial completion:  GO-NICE: A Study to Investigate the Use of Golimumab (Simponi®) in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554) (clinicaltrials.gov) -  Oct 28, 2015
P=N/A, N=1521, Completed,  Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting | N=15 --> 20 Active, not recruiting --> Completed

||||||||||  Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Trial primary completion date:  Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis (clinicaltrials.gov) -  Oct 27, 2015
P1, N=39, Completed,  Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Trial primary completion date: May 2014 --> Oct 2013

||||||||||  tazarotene topical / Generic mfg.
Trial primary completion date:  Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis (clinicaltrials.gov) -  Oct 22, 2015
P3, N=804, Recruiting,  Sponsor: G & W Laboratories Inc.
Trial primary completion date: May 2014 --> Oct 2013 Trial primary completion date: Jul 2015 --> Apr 2016

||||||||||  Cibinqo (abrocitinib) / Pfizer
Enrollment change, Trial termination:  Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis (clinicaltrials.gov) -  Oct 22, 2015
P2, N=61, Terminated,  Sponsor: Pfizer
N=196 --> 61 | Recruiting --> Terminated; Study terminated 26 June 2015 due to changes in the drug development portfolio. This study was not terminated for reasons of safety and/or efficacy

|||||||||| Enrollment change, Trial withdrawal: Evaluation of Vitamin D Levels in Psoriasis Patients (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=0, Withdrawn, Sponsor: University of California, Irvine
This study was not terminated for reasons of safety and/or efficacy N=75 --> 0 | Recruiting --> Withdrawn

||||||||||  Impoyz (clobetasol) / Encore
Enrollment closed:  DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) -  Sep 28, 2015
P2, N=50, Active, not recruiting,  Sponsor: Promius Pharma, LLC
N=75 --> 0 | Recruiting --> Withdrawn Recruiting --> Active, not recruiting

||||||||||  Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
Enrollment closed:  NAVIGATE: A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab (clinicaltrials.gov) -  Sep 28, 2015
P3, N=876, Active, not recruiting,  Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting

|||||||||| Trial primary completion date, Patient reported outcomes: Post Marketing Observational Study on Venezuelan Patients With Psoriasis (clinicaltrials.gov) - Sep 24, 2015
P=N/A, N=100, Suspended, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2015 --> May 2016

||||||||||  rose bengal disodium (PH-10) / Provectus
Enrollment closed:  A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10 (clinicaltrials.gov) -  Sep 17, 2015
P2, N=30, Active, not recruiting,  Sponsor: Provectus Pharmaceuticals
Trial primary completion date: Nov 2015 --> May 2016 Recruiting --> Active, not recruiting

||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion:  RAPID-PsA: Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis (clinicaltrials.gov) -  Sep 15, 2015
P3, N=409, Completed,  Sponsor: UCB BIOSCIENCES GmbH
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

||||||||||  Cibinqo (abrocitinib) / Pfizer
Enrollment open:  Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis (clinicaltrials.gov) -  Sep 10, 2015
P2, N=196, Recruiting,  Sponsor: Pfizer
Active, not recruiting --> Completed Active, not recruiting --> Recruiting

||||||||||  Enbrel (etanercept) / Pfizer, Amgen
Trial completion:  Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)? (clinicaltrials.gov) -  Sep 10, 2015
P3, N=60, Completed,  Sponsor: Assistance Publique Hopitaux De Marseille
Active, not recruiting --> Recruiting Recruiting --> Completed

|||||||||| Trial completion: Tacrolimus Versus Clobetasol Propionate in the Treatment of Vulvar Lichen Sclerosus (clinicaltrials.gov) - Sep 10, 2015
P2, N=56, Completed, Sponsor: Deana Funaro
Recruiting --> Completed Active, not recruiting --> Completed

||||||||||  calcipotriol/betamethasone dipropionate / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date:  A Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy (clinicaltrials.gov) -  Sep 8, 2015
P4, N=8, Completed,  Sponsor: University of Pittsburgh
Active, not recruiting --> Completed Recruiting --> Completed | N=15 --> 8 | Trial primary completion date: Jan 2014 --> Sep 2014

||||||||||  Enbrel (etanercept) / Pfizer, Amgen
Enrollment closed:  Study to Assess the Immunogenicity and Safety of Etanercept Produced in Plaque Psoriasis (clinicaltrials.gov) -  Sep 3, 2015
P4, N=132, Active, not recruiting,  Sponsor: Amgen
Recruiting --> Completed | N=15 --> 8 | Trial primary completion date: Jan 2014 --> Sep 2014 Recruiting --> Active, not recruiting

||||||||||  pefcalcitol (M 518101) / Maruho
Trial completion, Enrollment change:  Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis (clinicaltrials.gov) -  Sep 3, 2015
P3, N=480, Completed,  Sponsor: Maruho North America Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=360 --> 480

||||||||||  pefcalcitol (M 518101) / Maruho
Trial completion:  Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis (clinicaltrials.gov) -  Sep 3, 2015
P3, N=542, Completed,  Sponsor: Maruho North America Inc.
Active, not recruiting --> Completed | N=360 --> 480 Active, not recruiting --> Completed

||||||||||  pefcalcitol (M 518101) / Maruho
Trial completion:  Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis (clinicaltrials.gov) -  Sep 3, 2015
P3, N=537, Completed,  Sponsor: Maruho North America Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Enstilar (calcipotriene/betamethasone dipropionate) / LEO Pharma
Trial completion:  Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet (clinicaltrials.gov) -  Sep 1, 2015
P3, N=219, Completed,  Sponsor: LEO Pharma
Active, not recruiting --> Completed Recruiting --> Completed

||||||||||  Bimzelx (bimekizumab) / UCB
Clinical:  Multiple Dose Study of UCB4940 in Subjects With Psoriatic Arthritis (clinicaltrials.gov) -  Sep 1, 2015
P1, N=53, Completed,  Sponsor: UCB Celltech
Recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Xeljanz (tofacitinib) / Pfizer
Clinical:  A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis (clinicaltrials.gov) -  Sep 1, 2015
P3, N=266, Completed,  Sponsor: Pfizer
Active, not recruiting --> Completed Recruiting --> Completed

||||||||||  brepocitinib (PF-06700841) / Pfizer
PK/PD data:  A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation (clinicaltrials.gov) -  Aug 26, 2015
P1, N=89, Recruiting,  Sponsor: Pfizer
Recruiting --> Completed N=158 --> 89

||||||||||  Cibinqo (abrocitinib) / Pfizer
Trial primary completion date:  Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis (clinicaltrials.gov) -  Aug 21, 2015
P2, N=196, Active, not recruiting,  Sponsor: Pfizer
N=158 --> 89 Trial primary completion date: Feb 2016 --> Sep 2015

||||||||||  Cosentyx (secukinumab) / Novartis
Enrollment closed, Trial primary completion date:  Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab (clinicaltrials.gov) -  Aug 21, 2015
P3, N=237, Active, not recruiting,  Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Feb 2016 --> Sep 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Jun 2017

|||||||||| Biomarker, Trial primary completion date: Serum Lipid Levels and Other Biomarkers of Cardiovascular Disease in Patients With Psoriasis (clinicaltrials.gov) - Aug 20, 2015
P=N/A, N=200, Recruiting, Sponsor: George Washington University
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Jun 2017 Trial primary completion date: Jun 2015 --> Nov 2015

|||||||||| Trial primary completion date: A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis (clinicaltrials.gov) - Aug 20, 2015
P=N/A, N=370, Recruiting, Sponsor: George Washington University
Trial primary completion date: Jun 2015 --> Nov 2015 Trial primary completion date: Jul 2015 --> Nov 2015

||||||||||  Enbrel (etanercept) / Pfizer, Amgen
Enrollment closed:  Safety and Efficacy of Etanercept in Patients With Psoriasis (clinicaltrials.gov) -  Aug 19, 2015
P=N/A, N=80, Active, not recruiting,  Sponsor: Chengdu PLA General Hospital
Trial primary completion date: Jul 2015 --> Nov 2015 Recruiting --> Active, not recruiting

||||||||||  Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim
Trial completion:  BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab (clinicaltrials.gov) -  Aug 14, 2015
P2, N=166, Completed,  Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

||||||||||  Xeljanz (tofacitinib) / Pfizer
Clinical:  A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis (clinicaltrials.gov) -  Aug 13, 2015
P3, N=264, Recruiting,  Sponsor: Pfizer
Active, not recruiting --> Completed Trial primary completion date: Nov 2014 --> Aug 2015

||||||||||  Cosentyx (secukinumab) / Novartis
Trial primary completion date:  TRANSFIGURE: Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis (clinicaltrials.gov) -  Aug 13, 2015
P3, N=198, Active, not recruiting,  Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Nov 2014 --> Aug 2015 Trial primary completion date: Jan 2016 --> Jan 2017

||||||||||  Ossirene (AS101) / Cassiopea, Feramda
Enrollment change:  Topical Application of AS101 for the Treatment of Psoriasis (clinicaltrials.gov) -  Aug 13, 2015
P2, N=0, Withdrawn,  Sponsor: BioMAS Ltd
Trial primary completion date: Jan 2016 --> Jan 2017 N=70 --> 0

||||||||||  Enbrel (etanercept) / Pfizer, Amgen
Phase classification, HEOR:  Observational Study Evaluating Etanercept (Enbrel®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings (clinicaltrials.gov) -  Aug 13, 2015
P4, N=926, Completed,  Sponsor: Pfizer
N=70 --> 0 Phase classification: P=N/A --> P4

||||||||||  Humira (adalimumab) / Eisai, AbbVie
Enrollment closed:  Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities (clinicaltrials.gov) -  Aug 12, 2015
P=N/A, N=266, Active, not recruiting,  Sponsor: AbbVie (prior sponsor, Abbott)
Phase classification: P=N/A --> P4 Recruiting --> Active, not recruiting

||||||||||  Humira (adalimumab) / Eisai, AbbVie
Enrollment change, Adherence:  Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice (clinicaltrials.gov) -  Aug 12, 2015
P=N/A, N=140, Recruiting,  Sponsor: AbbVie
Recruiting --> Active, not recruiting N=80 --> 140



	Diseases Companies Products Productz Mechanisms of Action Sites